Allergy Asthma Immunol Res.  2015 Jul;7(4):312-320. 10.4168/aair.2015.7.4.312.

Seven Steps to the Diagnosis of NSAIDs Hypersensitivity: How to Apply a New Classification in Real Practice?

• Kowalski M
• Makowska J

• KMID: 2166678
• DOI: http://doi.org/10.4168/aair.2015.7.4.312

Abstract

Frequent use of non-steroidal anti-inflammatory drugs (NSAIDs) has been paralleled by increasing occurrence of adverse reactions, which vary from mild local skin rashes or gastric irritation to severe, generalized symptoms and even life-threatening anaphylaxis. NSAID-induced hypersensitivity reactions may involve both immunological and non-immunological mechanisms and should be differentiated from type A adverse reactions. Clinical diagnosis and effective management of a hypersensitive patient cannot be achieved without identifying the underlying mechanism. In this review, we discuss the current classification of NSAID-induced adverse reactions and propose a practical diagnostic algorithm that involves 7 steps leading to the determination of the type of NSAID-induced hypersensitivity and allows for proper patient management.

Keyword

Nonsteroidal anti-inflammatory drugs; NSAID-induced hypersensitivity; aspirin hypersensitivity; aspirin; drug allergy

MeSH Terms

Anaphylaxis
Anti-Inflammatory Agents, Non-Steroidal*
Aspirin
Classification*
Diagnosis*
Drug Hypersensitivity
Exanthema
Humans
Hypersensitivity*
Anti-Inflammatory Agents, Non-Steroidal
Aspirin

Figure

• 

  Fig. 1 NSAIDs-induced adverse reactions.

• 

  Fig. 2 Seven steps to the diagnosis of NSAID hypersensitivity reactions.

Reference

1. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012; 32:1491–1502.

2. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013; 68:1219–1232.

3. Stevenson DD, Kowalski ML. An epidemic of over diagnosing drug allergies. Allergy Asthma Proc. 2014; 35:92–94.

4. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001; 87:177–180.

5. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy. 2011; 66:818–829.

6. Torres MJ, Barrionuevo E, Kowalski M, Blanca M. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am. 2014; 34:507–524. vii–viii.

7. Vane JR. The mode of action of aspirin and similar compounds. J Allergy Clin Immunol. 1976; 58:691–712.

8. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993; 268:6610–6614.

9. Park HS, Kowalski ML, Sanchez-Borges M. Hypersensitivity to aspirin and other nonsteroidal antiinflammatory drugs. In : Adkinson NF, Bochner BS, Burks W, Busse WW, Holgate ST, Lemanske RF, O'Hehir RE, editors. Middleton's allergy: principles and practice. 8th ed. Philadelphia (PA): Elsevier/Saunders;2014. p. 1296–1309.

10. Hoitsma AJ, Wetzels JF, Koene RA. Drug-induced nephrotoxicity. Aetiology, clinical features and management. Drug Saf. 1991; 6:131–147.

11. Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968; 68:975–983.

12. Szczeklik A, Nizankowska E, Duplaga M. AIANE Investigators. European Network on Aspirin-Induced Asthma. Natural history of aspirin-induced asthma. Eur Respir J. 2000; 16:432–436.

13. Kowalski ML, Cieślak M, Pérez-Novo CA, Makowska JS, Bachert C. Clinical and immunological determinants of severe/refractory asthma (SRA): association with Staphylococcal superantigen-specific IgE antibodies. Allergy. 2011; 66:32–38.

14. Yoshimine F, Hasegawa T, Suzuki E, Terada M, Koya T, Kondoh A, et al. Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan. Respirology. 2005; 10:477–484.

15. Senna G, Bilò MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Eur Ann Allergy Clin Immunol. 2004; 36:215–218.

16. Quiralte J, Delgado J, Sáenz de San Pedro B, López-Pascual E, Nieto MA, Ortega N, et al. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2004; 93:360–364.

17. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors; emerging concepts. Allergy Asthma Immunol Res. 2014; 6:288–295.

18. Stevenson DD, Simon RA, Mathison DA, Christiansen SC. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol. 2000; 85:477–482.

19. Park SM, Park JS, Park HS, Park CS. Unraveling the genetic basis of aspirin hypersensitivity in asthma beyond arachidonate pathways. Allergy Asthma Immunol Res. 2013; 5:258–276.

20. Szczeklik A, Niżankowska-Mogilnicka E, Sanak M. Hypersensitivity to aspirin and other NSAIDs. In : Kay AB, Bousquet J, Holt PG, Kaplan AP, editors. Allergy and allergic diseases. 2nd ed. Hoboken (NJ): Wiley-Blackwell;2008. p. 1966–1979.

21. Doña I, Blanca-López N, Cornejo-García JA, Torres MJ, Laguna JJ, Fernández J, et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011; 41:86–95.

22. Kozel MM, Bossuyt PM, Mekkes JR, Bos JD. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: a systematic review. J Am Acad Dermatol. 2003; 48:409–416.

23. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004; 113:771–775.

24. Doña I, Blanca-López N, Jagemann LR, Torres MJ, Rondón C, Campo P, et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. Allergy. 2011; 66:1428–1433.

25. Kowalski ML, Bienkiewicz B, Woszczek G, Iwaszkiewicz J, Poniatowska M. Diagnosis of pyrazolone drug sensitivity: clinical history versus skin testing and in vitro testing. Allergy Asthma Proc. 1999; 20:347–352.

26. Rutkowski K, Nasser SM, Ewan PW. Paracetamol hypersensitivity: clinical features, mechanism and role of specific IgE. Int Arch Allergy Immunol. 2012; 159:60–64.

27. Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F, et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol. 2003; 111:882–888.

28. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329:15–19.

29. Gebhardt M, Wollina U. Cutaneous side-effects of nonsteroidal anti-inflammatory drugs (NSAID). Z Rheumatol. 1995; 54:405–412.

30. Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol. 2008; 74:430.

31. Barbaud A. Contact dermatitis due to topical drugs. G Ital Dermatol Venereol. 2009; 144:527–536.

32. Ward KE, Archambault R, Mersfelder TL. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature. Am J Health Syst Pharm. 2010; 67:206–213.

33. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS. SCAR Study Group. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol. 2003; 30:2234–2240.

34. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007; 157:989–996.

35. Mihovilovic K, Ljubanovic D, Knotek M. Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs. Clin Drug Investig. 2011; 31:351–355.

36. Ameen KH, Pinninti R, Jami S. Aceclofenac induced Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. J Pharmacol Pharmacother. 2013; 4:69–71.

37. Rozieres A, Vocanson M, Saïd BB, Nosbaum A, Nicolas JF. Role of T cells in nonimmediate allergic drug reactions. Curr Opin Allergy Clin Immunol. 2009; 9:305–310.

38. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003; 139:683–693.

39. Doña I, Blanca-López N, Torres MJ, García-Campos J, García-Núñez I, Gómez F, et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012; 22:363–371.

40. Bavbek S, Ikincioğullari A, Dursun AB, Guloğlu D, Arikan M, Elhan AH, et al. Upregulation of CD63 or CD203c alone or in combination is not sensitive in the diagnosis of nonsteroidal anti-inflammatory drug intolerance. Int Arch Allergy Immunol. 2009; 150:261–270.

41. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007; 62:1111–1118.

42. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007; 98:172–174.

43. Nizankowska E, Bestyńska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J. 2000; 15:863–869.

44. Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol. 1998; 101:581–586.